Workflow
共同药业连亏1年半 2021上市中信证券保荐两募资共6亿
Zhong Guo Jing Ji Wang·2025-10-21 06:48

Financial Performance - In the first half of 2025, the company achieved operating revenue of 302 million CNY, representing a year-on-year increase of 29.33% compared to 233 million CNY in the same period last year [1][2] - The net profit attributable to shareholders was -11.15 million CNY, a decline of 117.88% from -5.12 million CNY in the previous year [1][2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -10.22 million CNY, down 107.42% from -4.93 million CNY year-on-year [1][2] - The net cash flow from operating activities was -5.79 million CNY, a significant decrease of 116.98% from 34.11 million CNY in the same period last year [1][2] Previous Year Performance - In 2024, the company reported operating revenue of 537 million CNY, a decrease of 5.26% compared to the previous year [2] - The net profit attributable to shareholders was -27.59 million CNY, compared to a profit of 23 million CNY in the same period last year [2] - The net profit after deducting non-recurring gains and losses was -28.22 million CNY, down from a profit of 20.96 million CNY year-on-year [2] - The net cash flow from operating activities was -20.59 million CNY, compared to 68.13 million CNY in the previous year [2] Fundraising Activities - The company went public on the Shenzhen Stock Exchange's ChiNext board on April 9, 2021, issuing 29 million shares at a price of 8.24 CNY per share, raising a total of 238.96 million CNY [3] - The net proceeds from the public offering after deducting issuance costs were 194.18 million CNY, intended for production projects and working capital [3] - On December 13, 2022, the company announced the issuance of convertible bonds, raising a total of 380 million CNY, with net proceeds of 373.22 million CNY after costs [4] - The total amount raised from both fundraising activities was 618.96 million CNY [5]